Silmitasertib

DB15408InvestigationalSmall molecule

Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).

Mechanism: Pharmacologically active on Casein kinase II subunit alpha
Curator reviewed
Formula / weight: C₁₉H₁₂ClN₃O₂ · 349.77 g/mol (avg)
Code names: CX-4945

Resolves to

Compound

UNIIC6RWP0N0L2CAS1009820-21-6ChEMBLCHEMBL1230165

Structure

InChIKeyMUOKSQABCJCOPU-UHFFFAOYSA-NSMILESOC(=O)C1=CC2=C(C=C1)C1=C(C=CN=C1)C(NC1=CC(Cl)=CC=C1)=N2

Targets

P68400CSNK2A1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Silmitasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account